Latest Germany News

Vulcan Energy has unveiled a Preliminary Feasibility Study for Project Ludwig, its second lithium and geothermal phase in Germany, projecting stronger economics and a repeatable growth model.

Collins Foods posted record FY26 revenue and underlying profit, exited Taco Bell to focus on KFC growth, and outlined ambitious expansion plans in Germany and Australia.

BLS Pharmaceuticals (ASX: BLS) reported a standout FY26 with revenue surging 161% to $74.2 million and net profit more than tripling to $15.4 million, driven by expanded manufacturing and major international contracts including a $50 million German supply deal.

Adslot Ltd swung to a $4.2 million profit in FY2026, buoyed by a $6 million non-cash gain from deconsolidating its troubled subsidiary. The company’s restructuring efforts trimmed costs by 28%, but revenue fell 10%.

Clever Culture Systems expanded its pharmaceutical customer base to eight in FY26, placing 11 APAS Independence instruments and completing its product offering with a contact plate module. Despite a $2.24 million net loss, the company expects meaningful sales growth in FY27 backed by a robust pipeline and disciplined financial management.

OncoSil Medical lifted revenues 44% in FY26 to $1.68 million and trimmed losses by 28% to $10.86 million, buoyed by key regulatory approvals including FDA HDE and Australian TGA listings. The company is poised for commercial launches in the US and Australia, with strong clinical data underpinning its growth.

4DMedical’s CT:VQ™ lung imaging technology secured FDA clearance and CMS reimbursement, driving rapid adoption in top US medical centres and expanding its addressable market to $3 billion with new clinical programs and European contracts.

Spacetalk Ltd reported a 17% revenue decline in FY26 amid a strategic reset, but mobile revenue grew 16% as the company pivots to a software-led family safety platform supported by new telco partnerships.

ECS Botanics boosted revenue by 10% to $21.4 million in FY26, delivering positive EBITDA and operating cash flow while advancing international market entry and branded product growth.

Rua Bioscience's FY26 results highlight a 71% surge in customer revenue driven by international expansion, yet the company continues to face significant losses and going concern risks.

Neuren Pharmaceuticals reported an 8% rise in H1 2026 revenues driven by DAYBUE royalties, but profit fell 68% due to ramped-up R&D. The company declared its first ever dividend, signalling confidence amid ongoing clinical and regulatory milestones.

Lovisa Holdings reported a robust FY26 with revenue up 17.6% to A$938.8 million, expanded its global store network to 1,136 locations, and declared a 33 cent final dividend, reflecting strong momentum in key markets.